听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览SEMINARS IN ONCOLOGY期刊下所有文献
  • Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.

    abstract::This article summarizes the likely attenuation properties of RRx-001 in COVID-19 based on its mechanism of action and the putative pathogenesis of the disease, which appears to activate inflammatory, oxidative, and immune cascades with the potential to culminate in acute respiratory distress syndrome, cytokine storm a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2020.07.002

    authors: Oronsky B,Knox S,Cabrales P,Oronsky A,Reid TR

    更新日期:2020-10-01 00:00:00

  • Are sex discordant outcomes in COVID-19 related to sex hormones?

    abstract::COVID-19 has a clear sex disparity in clinical outcome. Globally, infection rates between men and women are similar; however, men are more likely to have more severe disease and are more likely to die. The causes for this disparity are currently under investigation and are most likely multifactorial. Sex hormones play...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2020.06.002

    authors: Strope JD,Chau CH,Figg WD

    更新日期:2020-10-01 00:00:00

  • Novel radiation therapy approaches for breast cancer treatment.

    abstract::The role of radiation therapy in the management of breast cancer continues to evolve. For patients with early stage breast cancer, hypofractionated whole breast irradiation following breast conserving surgery now represents the standard of care based on randomized data with long-term efficacy and toxicity outcomes. Pa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2020.05.003

    authors: Shah C,Bauer-Nilsen K,McNulty RH,Vicini F

    更新日期:2020-08-01 00:00:00

  • Tools of the trade to address schooling related communication needs after childhood cancer: A mini-review with consideration of health disparity concerns.

    abstract::Over the last 60 years, success rates in treating childhood cancers have grown dramatically from 10% to greater than 85%. Negative effects of treatments, however, place survivors at risk for neurocognitive deficits that can make school challenging. Evidence shows that receiving special education services can benefit a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1053/j.seminoncol.2020.02.003

    authors: Paré-Blagoev EJ,Ruble K,Jacobson LA

    更新日期:2020-02-01 00:00:00

  • Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review.

    abstract:BACKGROUND:Patients with severe renal impairment or undergoing hemodialysis are usually excluded from clinical trials. Available data regarding safety and activity of systemic therapies (ST) in hemodialyzed patients are scarce. METHODS:Clinical data were searched through PubMed database until April 2020 according to P...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2020.05.001

    authors: Klajer E,Garnier L,Goujon M,Schlurmann-Constans F,Mery B,Nguyen Tan Hon T,Mouillet G,Calcagno F,Thiery-Vuillemin A

    更新日期:2020-01-01 00:00:00

  • Treatment specific toxicities: Hormones, antihormones, radiation therapy.

    abstract::Session IV of the Second International Colloquium on Cardio-Oncology held in Kraków, focused on the cardiovascular risks of using hormone replacement therapy in breast cancer and androgen deprivation therapy in prostate cancer and continued the theme from Session 3 with a discussion of risk reduction strategies. The d...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2019.01.006

    authors: Plummer C,Steingart RM,Jurczak W,Iakobishvili Z,Lyon AR,Plastaras JP,Minotti G

    更新日期:2019-12-01 00:00:00

  • Cardio-oncology in clinical studies and real life.

    abstract::Session V of the Colloquium was chaired by Professors Teresa López-Fernández of Spain and Grzegorz Opolski of Poland. The 3 speakers addressed cardio-oncology issues as they relate to both clinical studies and real life situations. Professor Susan Dent discussed cardio-oncology networks for patients, emphasizing the i...

    journal_title:Seminars in oncology

    pub_type:

    doi:10.1053/j.seminoncol.2019.01.004

    authors: Dent SF,Suter TM,López-Fernández T,Opolski G,Menna P,Minotti G

    更新日期:2019-12-01 00:00:00

  • Neoadjuvant Treatment for Pancreatic Cancer.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.12.002

    authors: Raufi AG,Manji GA,Chabot JA,Bates SE

    更新日期:2019-02-01 00:00:00

  • The National Cancer Institute and Department of Veterans Affairs Interagency Group to Accelerate Trials Enrollment (NAVIGATE): A federal collaboration to improve cancer care.

    abstract::Cancer clinical trials represent an important option for patients with a diagnosis of cancer and the clinician-investigators involved in their care who seek options for their disease. For all who are impacted by cancer, these studies offer opportunities for greater learning. Conducting these important studies involves...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2019.09.005

    authors: Schiller SJ,Shannon C,Brophy MT,Denicoff AM,Good MJ,Prindiville SA,Huang GD

    更新日期:2019-01-01 00:00:00

  • The Veterans Precision Oncology Data Commons: Transforming VA data into a national resource for research in precision oncology.

    abstract::The Department of Veterans Affairs (VA) has a strong track record providing high-quality, evidence-based care to cancer patients. In order to accelerate discoveries that will further improve care for Veterans with cancer, the VA has partnered with the Center for Translational Data Science at the University of Chicago ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2019.09.002

    authors: Do N,Grossman R,Feldman T,Fillmore N,Elbers D,Tuck D,Dhond R,Selva L,Meng F,Fitzsimons M,Ajjarapu S,Ayandeh S,Hall R,Do S,Brophy M

    更新日期:2019-01-01 00:00:00

  • Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.

    abstract::Over 50% of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have stage IV disease at presentation and the most likely organ to be affected by metastases is the liver. Hepatic involvement and hepatic tumor burden is a key prognostic factor affecting survival of these patients and 80% eventually di...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.07.002

    authors: Keutgen XM,Schadde E,Pommier RF,Halfdanarson TR,Howe JR,Kebebew E

    更新日期:2018-08-01 00:00:00

  • Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy.

    abstract::Metastatic cancers during pregnancy have historically been associated with dismal outcomes, with greater rates of tumor progression in part because of diminished treatment alternatives. Immunotherapy with T-cell checkpoint inhibitors has significantly impacted the survival of several metastatic tumors. However, given ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2018.03.003

    authors: Burotto M,Gormaz JG,Samtani S,Valls N,Silva R,Rojas C,Portiño S,de la Jara C

    更新日期:2018-06-01 00:00:00

  • Nimotuzumab: beyond the EGFR signaling cascade inhibition.

    abstract::One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activates multiple signaling cascades that promote carcinogenesis and immune evasion. Therefore, these molecules have been extensively targeted in cancer immunotherapy. Beyond EGFR signaling cascade inhibition, some of these agen...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.04.008

    authors: Mazorra Z,Chao L,Lavastida A,Sanchez B,Ramos M,Iznaga N,Crombet T

    更新日期:2018-01-01 00:00:00

  • Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.

    abstract::Cyclin dependent kinase (CDK) 4/6 inhibitors have advanced the treatment of metastatic breast cancer by targeting the cell cycle machinery, interrupting intracellular and mitogenic hormone signals that stimulate proliferation of malignant cells. Preclinical evidence demonstrated that derangements of cyclin D1, CDK4/6,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.01.006

    authors: Scott SC,Lee SS,Abraham J

    更新日期:2017-12-01 00:00:00

  • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.

    abstract::The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2017.08.004

    authors: Capoluongo E,Ellison G,López-Guerrero JA,Penault-Llorca F,Ligtenberg MJL,Banerjee S,Singer C,Friedman E,Markiefka B,Schirmacher P,Büttner R,van Asperen CJ,Ray-Coquard I,Endris V,Kamel-Reid S,Percival N,Bryce J,Röthlisbe

    更新日期:2017-06-01 00:00:00

  • Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.

    abstract::Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for tr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1053/j.seminoncol.2017.01.001

    authors: Kazandjian D,Keegan P,Suzman DL,Pazdur R,Blumenthal GM

    更新日期:2017-02-01 00:00:00

  • Treatment of newly diagnosed myeloma: Bortezomib-based triplet.

    abstract::We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall su...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2016.11.003

    authors: Rajan AM,Rajkumar SV

    更新日期:2016-12-01 00:00:00

  • Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand.

    abstract::Publicly funded cancer medicines listed on the New Zealand Pharmaceutical Schedule were compared with those listed on the Australian Pharmaceutical Benefits Scheme. To quantify the health gains offered by the cancer medicines funded in Australia but not in New Zealand, clinical trial data reporting median progression-...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.10.004

    authors: Evans J,Laking G,Strother M,Wang T,Metcalfe S,Blick G,Pauls R,Crausaz S

    更新日期:2016-12-01 00:00:00

  • Genetic changes associated with testicular cancer susceptibility.

    abstract::Testicular germ cell tumor (TGCT) is a highly heritable cancer primarily affecting young white men. Genome-wide association studies (GWAS) have been particularly effective in identifying multiple common variants with strong contribution to TGCT risk. These loci identified through association studies have implicated mu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.08.004

    authors: Pyle LC,Nathanson KL

    更新日期:2016-10-01 00:00:00

  • The root causes of pharmacodynamic assay failure.

    abstract::Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or variable to fulfill this role. Our experience suggests that variable reag...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.06.006

    authors: Ferry-Galow KV,Makhlouf HR,Wilsker DF,Lawrence SM,Pfister TD,Marrero AM,Bigelow KM,Yutzy WH,Ji JJ,Butcher DO,Gouker BA,Kummar S,Chen AP,Kinders RJ,Parchment RE,Doroshow JH

    更新日期:2016-08-01 00:00:00

  • Cutaneous manifestations of lung cancer.

    abstract::Skin findings can serve as a clue to internal disease. In this article, cutaneous manifestations of underlying lung malignancy are reviewed. Paraneoplastic dermatoses are rare, but when recognized early, can lead to early diagnosis of an underlying neoplasm. Malignancy-associated dermatoses comprise a broad group of h...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.02.025

    authors: Owen CE

    更新日期:2016-06-01 00:00:00

  • Richter syndrome: pathogenesis and management.

    abstract::Richter syndrome (RS) is the development of an aggressive lymphoma in patients with a previous or concomitant diagnosis of chronic lymphocytic leukemia (CLL). The incidence rate RS is ~0.5% per year of observation. Two biomarkers (NOTCH1 mutations and subset 8 configuration of the B-cell receptor) may help identifying...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.02.012

    authors: Rossi D,Gaidano G

    更新日期:2016-04-01 00:00:00

  • Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

    abstract::In the last decade our understanding of chronic lymphocytic leukemia (CLL) biology and pathogenesis has increased substantially. These insights have led to the development of several new agents with novel mechanisms of action prompting a change in therapeutic approaches from chemotherapy-based treatments to targeted t...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.02.007

    authors: Herman SE,Wiestner A

    更新日期:2016-04-01 00:00:00

  • Alternate dosing schedules for cancer chemopreventive agents.

    abstract::Pharmacologic interventions for cancer risk reduction involve the chronic administration of synthetic or natural agents to reduce or delay the occurrence of malignancy. Despite the strong evidence for a favorable risk-benefit ratio for a number of agents in several common malignancies such as breast and prostate cance...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.09.014

    authors: Lazzeroni M,DeCensi A

    更新日期:2016-02-01 00:00:00

  • The Bayesian basket design for genomic variant-driven phase II trials.

    abstract::Basket clinical trials are a new category of early clinical trials in which a treatment is evaluated in a population of patients with tumors of various histologic types and primary sites selected for containing specific genomic abnormalities. The objective of such studies is generally to discover histologic types in w...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2016.01.002

    authors: Simon R,Geyer S,Subramanian J,Roychowdhury S

    更新日期:2016-02-01 00:00:00

  • MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.

    abstract::Aberrant activation of the three-layered protein kinase cascade, Raf/MEK/ERK, is often detected in human cancer, which is mainly attributed to the oncogenic alterations of RAF, or its upstream activators RAS or cell surface receptor tyrosine kinases. Deregulated activity of the Raf/MEK/ERK pathway drives uncontrolled ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.09.023

    authors: Wu PK,Park JI

    更新日期:2015-12-01 00:00:00

  • Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.

    abstract::In non-small cell lung cancer (NSCLC), the first immune checkpoint inhibitor to be approved by the US Food and Drug Administration was nivolumab, based on a survival advantage over docetaxel in recurrent squamous NSCLC, a difficult-to-treat histology. In addition, several other immune checkpoint inhibitors are also in...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.09.019

    authors: Garon EB

    更新日期:2015-10-01 00:00:00

  • Cooperative Group Trials in the Community Setting.

    abstract::Over the last 40 years the National Cancer Institute (NCI) has created a vibrant public-private partnership for the implementation of NCI-sponsored cooperative group (Network) clinical trials throughout the United States and Canada. Over these four decades, the cancer clinical trials process has become more complex mo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.07.011

    authors: Lloyd Wade J 3rd,Petrelli NJ,McCaskill-Stevens W

    更新日期:2015-10-01 00:00:00

  • Validation of the Concept of a Common Typical Time of Disease Duration for Hepatocellular Carcinoma Patients Using the Fisher Information Processing of Tumor Imaging Results Combined With Network Phenotyping Strategy Quantification of Individual Patient C

    abstract::A primary goal of current clinical cancer research is the identification of prognostic tumor subtypes. It is increasingly clear that tumor growth depends on both internal tumor factors, and factors that are external to the tumor, such as microenvironment. We recently showed that parameter values alone are less importa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2015.05.004

    authors: Pančoška P,Skála L,Nešetřil J,Carr BI

    更新日期:2015-08-01 00:00:00

  • Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

    abstract::Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.05.006

    authors: Obeid J,Hu Y,Slingluff CL Jr

    更新日期:2015-08-01 00:00:00

  • Epigenetics meets immune checkpoints.

    abstract::Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availab...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.02.003

    authors: Covre A,Coral S,Di Giacomo AM,Taverna P,Azab M,Maio M

    更新日期:2015-06-01 00:00:00

  • Toxicity patterns with immunomodulating antibodies and their combinations.

    abstract::Immune checkpoint molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), but also LAG-3 and TIM-3, are involved in regulation of peripheral tolerance in order to prevent autoimmunity. Blocking of these cell surface proteins by antibodies has resulted in remarkable anti-tumor immunity; howev...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.02.011

    authors: Haanen JB,Thienen Hv,Blank CU

    更新日期:2015-06-01 00:00:00

  • Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection.

    abstract::The human gammaherpesvirus family includes Epstein-Barr virus (EBV) and human herpesvirus (HHV)-8, also known as Kaposi sarcoma-associated herpesvirus (KSHV). In human immunodeficiency virus (HIV)-infected patients, both EBV and KSHV have been implicated in the development of a wide range of tumors. KSHV-associated di...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.026

    authors: Pinzone MR,Berretta M,Cacopardo B,Nunnari G

    更新日期:2015-04-01 00:00:00

  • Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma.

    abstract::Malignant biliary obstruction, duodenal, and gastric outlet obstruction, and tumor-related pain are the complications of unresectable pancreatic adenocarcinoma that most frequently require palliative intervention. Surgery involving biliary bypass with or without gastrojejunostomy was once the mainstay of treatment in ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.014

    authors: Stark A,Hines OJ

    更新日期:2015-02-01 00:00:00

  • Pathological and molecular evaluation of pancreatic neoplasms.

    abstract::Pancreatic neoplasms are morphologically and genetically heterogeneous and include a wide variety of tumors ranging from benign to malignant with an extremely poor clinical outcome. Our understanding of these pancreatic neoplasms has improved significantly with recent advances in cancer sequencing. Awareness of molecu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.004

    authors: Rishi A,Goggins M,Wood LD,Hruban RH

    更新日期:2015-02-01 00:00:00

  • Photodynamic therapy for lung cancer and malignant pleural mesothelioma.

    abstract::Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen ((1)O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. PDT is increasingly being used to treat thoracic mali...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.09.017

    authors: Simone CB 2nd,Cengel KA

    更新日期:2014-12-01 00:00:00

  • From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

    abstract::Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise revi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.08.005

    authors: Caruana I,Diaconu I,Dotti G

    更新日期:2014-10-01 00:00:00

  • Response patterns of recurrent glioblastomas treated with tumor-treating fields.

    abstract::Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effective standard treatment for recurrent GBM. NovoTTF Therapy is a novel...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2014.09.009

    authors: Vymazal J,Wong ET

    更新日期:2014-10-01 00:00:00

  • Oligodendroglial tumors.

    abstract::Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or IDH-1 mutations appear to be particularly sensitive to treatment. I...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.06.009

    authors: Jaeckle KA

    更新日期:2014-08-01 00:00:00

  • Involvement of platelet-derived microparticles in tumor progression and thrombosis.

    abstract::Platelet-derived microparticles (PMPs) represent the most abundant microparticle (MP) subtype. Their presence reflects platelet activity, physiopathology, and the thrombotic state of cancer patients. The quantity and composition of PMPs strictly depends on the way MPs were generated. Because platelets play a key role ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.04.010

    authors: Mezouar S,Mege D,Darbousset R,Farge D,Debourdeau P,Dignat-George F,Panicot-Dubois L,Dubois C

    更新日期:2014-06-01 00:00:00

441 条记录 1/12 页 « 12345678...1112 »